[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anemia-associated-with-chronic-kidney-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anemia-associated-with-chronic-kidney-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100651072","effect-of-daprodustat-and-epoetin-alpha-on-anemia-in-patients-not-undergoing-dialysis-100651072",false,"NCT07755683","Effect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis","Inclusion Criteria:\n\n1. Age 18-65 years, either gender.\n2. Confirmed CKD stage 3, 4, or 5.\n3. Not currently receiving dialysis at time of screening.\n4. Hemoglobin at presentation: 8.0-10 g\u002FdL, serum ferritin \\> 100 ng\u002FmL at screening and transferrin saturation (TSAT) \\> 20% at screening.\n\nExclusion Criteria:\n\n1. Clinically significant gastrointestinal bleeding, major surgery or RBCs transfusion in last 4 weeks\n2. Pregnant, breast-feeding, not agreed to use contraception\n3. Uncontrolled hypertension (\\>180\u002F100 mmHg).\n4. Recent major cardiovascular event including acute coronary syndrome or stroke, or in the past 3 months, chronic liver disease (ALT OR AST \\> 40 IU, hepatitis B or C)\n5. Use of any experimental\u002Finvestigational drug within 30 days of screening or know hypersensitivity against trial drugs\n6. Active or high risk malignancy or treatment for malignancy with in the past 2 years.\n7. Uncorrected iron deficiency despite iron supplementations.\n8. Acute sepsis as evident by increase C-reactive protein (CRP), Total leukocyte count (TLC).","ALL","18 Years","65 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","Anemia in CKD patients is mainly attributed to impaired kidney being unable to adequately respond to hypoxia and\u002For anaemia by inducing erythropoietin (EPO) production iron disorders, blood loss, shortened erythrocyte survival time and inflammation. High mortality among patients with advanced renal failure is directly related to the severity of anemia and hypoalbuminemia, particularly within the first six months.4, 5 Currently, the main treatment modalities for anemia in CKD include injections of erythropoiesis stimulating agents (ESAs), iron supplementation, and blood transfusion. EPO resistance and iron refractory anemia require red blood cell transfusions.\n\nThe rationale of this study is to compare the effectiveness of daprodustat versus epoetin alpha on hemoglobin level in patients with chronic kidney disease not on hemodialysis. Literature showed that epoetin alpha has better effectiveness in improving hemoglobin level and curing anemia in CKD patients. But conflicting results have been osbevred showing no difference in both drugs. In routine, both drugs are recommended for anemia in non-dialysis CKD patients. This trial is planned to check the effect of Daprodustat in patients not undergoing dialysis is primarily to provide an effective, orally administered alternative to current injectable anemia treatments, which are associated with several limitations and safety concerns. The treatment strategies and effectiveness optimization for patients with chronic kidney disease complicated by anemia remain a key issue that urgently needs to be addressed.",[26,27],"Chronic Kidney Disease (Stages 3b-5)","Anemia Associated With Chronic Kidney Disease",[29,30,31],"Anemia","Daprodustat","Epoetin Alpha","NOT_YET_RECRUITING","2026-08-04",{"date":35,"type":36},"2026-08-10","ACTUAL",{"date":38,"type":20},"2026-09-01",{"date":40,"type":20},"2027-02-28",{"name":42,"class":43},"Services Hospital, Lahore","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100636439","phase-3-safety-and-efficacy-of-a-phased-transition-from-epogen-to-three-times-weekly-oral-vadadustat-for-the-treatment-of-anemia-in-subjects-receiving-in-center-hemodialysis-100636439","NCT07565701","Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis","VOTE","Inclusion Criteria:\n\n* Adult patients ≥18 years of age\n* Receiving outpatient in-center hemodialysis for ESKD at least TIW (prescribed)\n* Currently receiving EPO (active administration, not on HOLD)\n* Less than or equal to 0.75 g\u002Fd difference between last 2 Hgb values prior to Screening, with neither Hgb \\\u003C9 g\u002FdL\n* Average of last 2 Hgb between 9-11.4 g\u002FdL (inclusive) prior to Screening\n* Central Screening Hgb 9-11.4 g\u002FdL (inclusive)\n* Central Screening transferrin saturation greater than or equal to 20%\n* Central Screening serum ferritin greater than or equal to 100 ng\u002FmL\n* Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure\n\nExclusion Criteria:\n\n* Contraindication to receive vadadustat per United States Prescribing Information (USPI) including Screening liver function tests greater than 3x the upper limit of normal (ULN)\n* Electronic Medical Record (EMR)-documented history of cirrhosis or active, acute liver disease\n* EMR-documented history of currently active malignancy excluding non-melanomatous skin cancer and in-situ cervical cancer\n* Concomitant use of HIF-PHI or OAT1\u002FOAT3 inhibitors (probenecid, rifampicin, gemfibrozil, or teriflunomide)\n* Unable to comply with study requirements or in the opinion of a healthcare provider or member of the central study team, not clinically stable to participate in the study\n* Documented unplanned absence from dialysis greater than or equal to 3 times in 30 days prior to Screening (excluding rescheduled dialysis treatments)\n* Pregnant at time of consent (per subject self-report)",{"count":53,"type":20},100,[55],"PHASE3","The goal of this study is to assess if patients can be retained on long-term vadadustat therapy (and thus potentially benefit from the favorable safety profile) by incorporating a phased transition from Epogen to three times per week vadadustat (TIW-V), reducing the likelihood of GI intolerance through use of a lower vadadustat starting dose, and also reducing or eliminating the initial reduction in hemoglobin through the maintenance of low dose Epogen until target hemoglobin stability is achieved on a tolerable dose of TIW-V.",[27],"2026-04-27",{"date":60,"type":36},"2026-05-04",{"date":62,"type":20},"2026-04",{"date":64,"type":20},"2027-06",{"name":66,"class":67},"Geoff Block","NETWORK"]